Photo credit: SciDevNet
Copyright: Sven Torfinn / Panos
Africa Analysis: Benefits of the restarted R&D alliance
“Many people argue that donors’ influence over health research agendas in Africa remains too strong.” Linda Nordling
- The second phase of Europe-Africa clinical trials partnership has started
- It could help African countries increase their investment in health R&D
- African governments need to help sustain the gains to be made
The reboot of the Europe-Africa clinical trials alliance could make Africa invest in health R&D, writes Linda Nordling.
In 2010 in Mali’s capital Bamako, representatives from over two dozen African health ministries signed a ‘call for action’ urging their governments to allocate at least two per cent of health ministry budgets toresearch. 
The aim of the call was for African governments to take ownership of the research agenda, which at the time was viewed as too driven by international donor priorities.
View original post 126 more words